CAUTION: WHEN THIS DRUG IS GIVEN INTRAMUSCULARLY AND/OR INTRATHECALLY, IT SHOULD BE GIVEN ONLY TO HOSPITALIZED PATIENTS, SO AS TO PROVIDE CONSTANT SUPERVISION BY A PHYSICIAN.
RENAL FUNCTION SHOULD BE CAREFULLY DETERMINED AND PATIENTS WITH RENAL DAMAGE AND NITROGEN RETENTION SHOULD HAVE REDUCED DOSAGE. PATIENTS WITH NEPHROTOXICITY DUE TO POLYMYXIN B SULFATE USUALLY SHOW ALBUMINURIA, CELLULAR CASTS, AND AZOTEMIA. DIMINISHING URINE OUTPUT AND A RISING BUN ARE INDICATIONS FOR DISCONTINUING THERAPY WITH THIS DRUG.
NEUROTOXIC REACTIONS MAY BE MANIFESTED BY IRRITABILITY, WEAKNESS, DROWSINESS, ATAXIA, PERIORAL PARESTHESIA, NUMBNESS OF THE EXTREMITIES, AND BLURRING OF VISION. THESE ARE USUALLY ASSOCIATED WITH HIGH SERUM LEVELS FOUND IN PATIENTS WITH IMPAIRED RENAL FUNCTION AND/OR NEPHROTOXICITY.
THE CONCURRENT OR SEQUENTIAL USE OF OTHER NEUROTOXIC AND/OR NEPHROTOXIC DRUGS WITH POLYMYXIN B SULFATE, PARTICULARLY BACITRACIN, STREPTOMYCIN, NEOMYCIN, KANAMYCIN, GENTAMICIN, TOBRAMYCIN, AMIKACIN, CEPHALORIDINE, PAROMOMYCIN, VIOMYCIN, AND COLISTIN SHOULD BE AVOIDED.
THE NEUROTOXICITY OF POLYMYXIN B SULFATE CAN RESULT IN RESPIRATORY PARALYSIS FROM NEUROMUSCULAR BLOCKADE, ESPECIALLY WHEN THE DRUG IS GIVEN SOON AFTER ANESTHESIA AND/OR MUSCLE RELAXANTS.
USAGE IN PREGNANCY: THE SAFETY OF THIS DRUG IN HUMAN PREGNANCY HAS NOT BEEN ESTABLISHED.
POLYMYXIN B SUMMARY
Polymyxin B for Injection is one of a group of basic polypeptide antibiotics derived from B polymyxa (B aerosporous). Polymyxin B sulfate is the sulfate salt of Polymyxins B1 and B2, which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillacea). It has a potency of not less than 6000 polymyxin B units per mg, calculated on the anhydrous basis.
Polymyxin B for Injection is indicated for the following:
Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa.
Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa.
It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated:
H influenzae, specifically meningeal infections.
Escherichia coli, specifically urinary tract infections.
Aerobacter aerogenes, specifically bacteremia.
Klebsiella pneumoniae, specifically bacteremia.
NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Published Studies Related to Polymyxin B
Evaluation of the anti-endotoxin effects of polymyxin B in a feline model of endotoxemia. [2010.04]
Directed, effective therapies for feline sepsis are needed to reduce the high morbidity and mortality associated with this disease. We investigated the anti-endotoxin effects of polymyxin B (PMB) in a blinded, placebo controlled fashion, both ex vivo in a feline whole blood culture system and in vivo, using a low-dose endotoxin infusion in cats...
Polymyxin-B hemoperfusion and endotoxin removal: lessons from a review of the literature. 
Sepsis involves a complex interaction between bacterial toxins and the host immune system...
Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. [2009.06.17]
CONTEXT: Polymyxin B fiber column is a medical device designed to reduce blood endotoxin levels in sepsis. Gram-negative-induced abdominal sepsis is likely associated with high circulating endotoxin. Reducing circulating endotoxin levels with polymyxin B hemoperfusion could potentially improve patient clinical outcomes. OBJECTIVE: To determine whether polymyxin B hemoperfusion added to conventional medical therapy improves clinical outcomes (mean arterial pressure [MAP], vasopressor requirement, oxygenation, organ dysfunction) and mortality compared with conventional therapy alone... CONCLUSION: In this preliminary study, polymyxin B hemoperfusion added to conventional therapy significantly improved hemodynamics and organ dysfunction and reduced 28-day mortality in a targeted population with severe sepsis and/or septic shock from intra-abdominal gram-negative infections. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00629382.
A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. [2008.11]
PURPOSE: To compare the speed of clinical efficacy for two currently available topical antibiotics: polymyxin B sulfate/trimethoprim (polymyxin/trimethoprim) and 0.5% moxifloxacin ophthalmic solution... CONCLUSION: Moxifloxacin 0.5% administered three times daily is safe and cures bacterial conjunctivitis more effectively and significantly faster than polymyxin/trimethoprim dosed four times daily. The majority of patients were cured and symptom-free by 48 hours. Therefore, moxifloxacin is cost-effective and significantly more efficacious than polymyxin/trimethoprim in the speed by which it reduces the symptoms and disease transmission.
A comparison of ciprofloxacin/dexamethasone with neomycin/polymyxin/hydrocortisone for otitis externa pain. [2007.05]
Ciprofloxacin 0.3%/dexamethasone 0.1% (CIP/DEX) and neomycin 0.35%(polymyxin B 10,000 IU/mL/hydrocortisone 1.0% (NPH) were compared for relief of pain in patients with acute otitis externa. Patients received 7 d of treatment with CIP/DEX twice daily or NPH 3 times daily... Overall, these results support greater pain relief attained over the first 3 d in patients with acute otitis externa treated with CIP/DEX compared with NPH and a rapid reduction in severe pain after initiation of treatment.
Clinical Trials Related to Polymyxin B
Impact of Early Peri-operative Use of Polymyxin-B Hemoperfusion in Septic Patients Undergoing Emergent Abdominal Surgery [Recruiting]
Septic shock of intra-abdominal origin is likely due to Gram-negative bacteria or mixed
pathogens and associated with high levels of endotoxin. The injury to the endothelium
results in an increase of endothelial permeability, interstitial edema and release of nitric
oxide (NO) that is a very potent vasodilatator.  Polymyxins obtained from the
Gram-positive bacterium Bacillus polymyxa are antibiotics known for their ability to bind
LPS in the outer membrane of the Gram-negative bacterial cell wall as well as free
endotoxins with high affinity. Polymyxin-B has been shown to block the activation of cells
by a wide variety of LPS. Studies converged to show an improvement in the treatment of
septic shock by removing circulating endotoxin. Starting Polymyxin-B hemoperfusion during the
operative time is to block the initiation of various deleterious biological cascades induced
by endotoxemia such as systemic inflammation, disseminated coagulation disorders, and shock,
leading to organ dysfunction and death.
SDD for Eradicating CRKP Carriage [Not yet recruiting]
There is an urgent need to control the current national outbreak of Carbapenem-resistent
Klebsiella pneumonia (CRKP). In Israel, the death rate among CRKP carriers is 3. 5 times
higher than in Carbapenem-sensitive Klebsiella pneumonia carriers (44% vs. 12. 5%,
In the investigators' previous study: A Randomized, Double-Blind, Placebo-Controlled Trial
of Selective Digestive Decontamination (SDD) Using Oral Gentamicin and Oral Polymyxin E for
Eradication of CRKP Carriage (Infect Control Hosp Epidemiol. 2012;33: 14-19) the
investigators have shown that the investigators' SDD regimen is effective for decolonization
patients colonized with CRKP.
The investigators' assumption is that a higher dose of polymyxin E together with gentamicin
(SDD drugs) for a prolonged period is needed to overcome the likelihood of a high rate of
drug inactivation in the gut, thereby reaching CRKP carriage eradication.
Effectiveness of Polymixin B Sulphate + Prednisolone + Benzoacaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous [Not yet recruiting]
Dermatitis eczematous is a recurrent pruritic skin disorder which has a significant
morbidity and impaired quality of life due specially pruritus and physical visible skin
lesions. The propose of this trial is evaluate the effectiveness of two differents topic
associations of drugs.
Polymyxin-B Protects From Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial [Recruiting]
Aim of the study is to verify whether Polymyxin-B hemoperfusion protects from renal
dysfunction in patients with severe sepsis from gram negative infection
Efficacy Maxinom� And Maxitrol� in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis [Not yet recruiting]
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Polymyxin B has an overall score of 10. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
Polymyxin B review by 35 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || conjunctivitis|
|Dosage & duration:|| || 2 drops (dosage frequency: 3 times daily) for the period of 7 days|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || It relieved symptoms of conjuctivitis including iching, dryness, soreness, buildup of mucus and sensitivity to light. Symptoms seem to clear up quickly and render the patient non infectious after 24 hours of treatment. It can be given to pregnant women with no adverse effects to the unborn child|
|Side effects:|| || There did not seem to be any side effects to the use of the drug|
|Comments:|| || The drug is a liquid administered in an eye drop form. It is self delivered into the eye. 2 drops are given in the affected eye up to 3 to 4 times daily for a total of 7 to 10 days. |
Page last updated: 2010-10-05